<code id='FABDC3CDAF'></code><style id='FABDC3CDAF'></style>
    • <acronym id='FABDC3CDAF'></acronym>
      <center id='FABDC3CDAF'><center id='FABDC3CDAF'><tfoot id='FABDC3CDAF'></tfoot></center><abbr id='FABDC3CDAF'><dir id='FABDC3CDAF'><tfoot id='FABDC3CDAF'></tfoot><noframes id='FABDC3CDAF'>

    • <optgroup id='FABDC3CDAF'><strike id='FABDC3CDAF'><sup id='FABDC3CDAF'></sup></strike><code id='FABDC3CDAF'></code></optgroup>
        1. <b id='FABDC3CDAF'><label id='FABDC3CDAF'><select id='FABDC3CDAF'><dt id='FABDC3CDAF'><span id='FABDC3CDAF'></span></dt></select></label></b><u id='FABDC3CDAF'></u>
          <i id='FABDC3CDAF'><strike id='FABDC3CDAF'><tt id='FABDC3CDAF'><pre id='FABDC3CDAF'></pre></tt></strike></i>

          Home / explore / focus

          focus


          focus

          author:explore    Page View:248
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In